FindTrial
Sign In

Study to assess the combined effect of Pratimarsha Nasya, Avagundana and Aschyotana in Meibomian gland dysfunction (MGD)

Exploratory study to assess the combined effect of Pratimarsha Nasya, Avagundana and Aschyotana in Meibomian gland dysfunction - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/07/071440
Enrollment
30
Registered
2024-07-26
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H028- Other specified disorders of eyelid

Interventions

None listed

Sponsors

Dr Sreelekha P
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients within the age group of 20 – 70 years irrespective of sex. 2.Patients with signs and symptoms of MGD 3.Patients with MGD but with no other ocular pathology requiring treatment other than eye lubricant and conventional eyelid hygiene within the last month and during the study.

Exclusion criteria

Exclusion criteria: 1.Patients under long term medications, immunosuppressants and topical steroids. 2.Pregnant women and lactating mothers. 3.Patient of MGD with hyperkeratinisation, atrophy of glands and gland dropout.

Design outcomes

Primary

MeasureTime frame
SUBJECTIVE PARAMETER Ocular surface disease index (OSDI) questionnaire OBJECTIVE PARAMETERS. 1.Tear film break up time 2.Schirmer test 1 3.Fluoresceine staining 4.Anatomical duct obstruction by photograph (telangiectasia, capping of orifices, abnormal secretions) 5.Expressibility criteria Timepoint: Before and after treatment(0th day, 31st day, 46th day, 61st day)—

Secondary

MeasureTime frame
nilTimepoint: nil—

Countries

India

Contacts

Public ContactDr K Shanti

Amrita School of Ayurveda

sreelekhav7stone@gmail.com8589875341

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026